TW202246286A - 作為hiv整合酶抑制劑之四環雜環化合物 - Google Patents

作為hiv整合酶抑制劑之四環雜環化合物 Download PDF

Info

Publication number
TW202246286A
TW202246286A TW111105302A TW111105302A TW202246286A TW 202246286 A TW202246286 A TW 202246286A TW 111105302 A TW111105302 A TW 111105302A TW 111105302 A TW111105302 A TW 111105302A TW 202246286 A TW202246286 A TW 202246286A
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
hiv
ester
Prior art date
Application number
TW111105302A
Other languages
English (en)
Chinese (zh)
Inventor
提摩西 約翰 哈汀
約翰 A 麥克考利
于濤
永璉 張
Original Assignee
美商默沙東有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商默沙東有限責任公司 filed Critical 美商默沙東有限責任公司
Publication of TW202246286A publication Critical patent/TW202246286A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
TW111105302A 2021-02-16 2022-02-14 作為hiv整合酶抑制劑之四環雜環化合物 TW202246286A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163149927P 2021-02-16 2021-02-16
US63/149,927 2021-02-16

Publications (1)

Publication Number Publication Date
TW202246286A true TW202246286A (zh) 2022-12-01

Family

ID=80625127

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111105302A TW202246286A (zh) 2021-02-16 2022-02-14 作為hiv整合酶抑制劑之四環雜環化合物

Country Status (12)

Country Link
US (1) US11958864B2 (cg-RX-API-DMAC7.html)
EP (1) EP4294813B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024507788A (cg-RX-API-DMAC7.html)
KR (1) KR20230147131A (cg-RX-API-DMAC7.html)
CN (1) CN117083282B (cg-RX-API-DMAC7.html)
AR (1) AR124868A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022223241B2 (cg-RX-API-DMAC7.html)
CA (1) CA3208396A1 (cg-RX-API-DMAC7.html)
ES (1) ES3048138T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023009445A (cg-RX-API-DMAC7.html)
TW (1) TW202246286A (cg-RX-API-DMAC7.html)
WO (1) WO2022177840A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
CN116390924B (zh) 2020-09-30 2025-11-07 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
CR20260070A (es) 2021-01-19 2026-04-24 Gilead Sciences Inc COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315)
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024226485A1 (en) * 2023-04-28 2024-10-31 Merck Sharp & Dohme Llc Delivery devices for anti-hiv compounds
WO2026101812A1 (en) * 2024-11-07 2026-05-15 Merck Sharp & Dohme Llc Hiv integrase inhibitors for treatment of hiv infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2660239B1 (en) * 2008-07-25 2016-11-23 VIIV Healthcare Company Chemical compounds as synthetic intermediates
WO2010011812A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2395705T3 (es) * 2008-07-25 2013-02-14 Glaxosmithkline Llc Compuestos químicos
LT2620436T (lt) * 2010-09-24 2018-08-10 Shionogi & Co., Ltd. Pakeistojo policiklinio karbamoilpiridono darinio provaistas
WO2017113288A1 (en) * 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018140368A1 (en) * 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors

Also Published As

Publication number Publication date
WO2022177840A1 (en) 2022-08-25
CN117083282A (zh) 2023-11-17
ES3048138T3 (en) 2025-12-09
JP2024507788A (ja) 2024-02-21
KR20230147131A (ko) 2023-10-20
CA3208396A1 (en) 2022-08-25
CN117083282B (zh) 2026-05-29
AR124868A1 (es) 2023-05-10
US11958864B2 (en) 2024-04-16
EP4294813A1 (en) 2023-12-27
AU2022223241B2 (en) 2026-04-30
US20220259227A1 (en) 2022-08-18
AU2022223241A1 (en) 2023-08-24
MX2023009445A (es) 2023-08-25
EP4294813B1 (en) 2025-09-10

Similar Documents

Publication Publication Date Title
EP4294813B1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
US9951079B2 (en) Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
EP3397639B1 (en) Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
US10233193B2 (en) Fused tricyclic heterocyclic compounds useful for treating HIV infection
EP3752144B1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
US10548910B2 (en) Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
US10624912B2 (en) Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors
US10544155B2 (en) Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
EP3801543B1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
US10934312B2 (en) Tricyclic heterocycle compounds useful as HIV integrase inhibitors
EP2875024A1 (en) Hiv treatment with amido-substituted pyrimidinone derivatives
US20150203512A1 (en) Macrocyclic compounds as hiv integrase inhibitors
US10786488B2 (en) Substituted quinolizine derivatives useful as HIV integrase inhibitors
KR20210005139A (ko) Hiv 인테그라제 억제제로서 유용한 트리시클릭 헤테로사이클 화합물
CN112384510A (zh) Rip1抑制性化合物以及制备和使用其的方法
RU2851203C2 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
US20210115044A1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors